Raymond James & Associates »

Eyepoint Pharmaceuticals shares owned by Raymond James & Associates

Quarter-by-quarter ownership of Eyepoint Pharmaceuticals (EYPT) shares owned by Raymond James & Associates from 13F filings

Historical chart of Raymond James & Associates investment in Eyepoint Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Eyepoint Pharmaceuticals held by Raymond James & Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eyepoint Pharmaceuticals by Raymond James & Associates

Quarter filed Position value Share count Share price at filing
2024-09-30 $86k 11k 7.99

More positions owned by Raymond James & Associates

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Ishares Tr Core Msci Eafe (IEFA)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Ishares Tr Core S&p Mcp Etf (IJH)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Home Depot (HD)
UnitedHealth (UNH)

View all positions for Raymond James & Associates

Top funds holding Eyepoint Pharmaceuticals

Cormorant Asset Management
Suvretta Capital Management
BlackRock
Franklin Resources
BlackRock
Vanguard Group
T. Rowe Price Associates
Morgan Stanley
Federated Investors
Citadel Advisors
Patient Square Capital
T. Rowe Price Investment Management
State Street Corporation
Geode Capital Management
Octagon Capital Advisors

View all funds holding Eyepoint Pharmaceuticals